|
|
| | tert-Butyl 2-bromo-4-fluorobenzoate Basic information |
| Product Name: | tert-Butyl 2-bromo-4-fluorobenzoate | | Synonyms: | tert-Butyl 2-bromo-4-fluorobenzoate;4-Bromo-2-fluoro-benzoic acid tert-butyl ester;2-Methylpropan-2-yl 4-bromo-2-fluorobenzoate;Benzoic acid,4-bromo-2-fluoro-, 1,1-dimethylethyl ester;tera-butyl 4-Bromo-2-fluorobenzoate;tert-Butyl 2-fluoro-4-bromobenzoate | | CAS: | 889858-12-2 | | MF: | C11H12BrFO2 | | MW: | 275.11 | | EINECS: | | | Product Categories: | | | Mol File: | 889858-12-2.mol |  |
| | tert-Butyl 2-bromo-4-fluorobenzoate Chemical Properties |
| Boiling point | 305.7±27.0 °C(Predicted) | | density | 1.394±0.06 g/cm3(Predicted) | | storage temp. | 2-8°C | | solubility | Chloroform (Slightly), Methanol (Slightly) | | form | Oil | | color | Clear Colourless |
| | tert-Butyl 2-bromo-4-fluorobenzoate Usage And Synthesis |
| Uses | tert-Butyl 4-Bromo-2-fluorobenzoate is an intermediate of enzalutamide (M199800). Enzalutamide is an androgen-receptor antagonist that blocks androgens from binding to the androgen receptor and prevents nuclear translocation and co-activator recruitment of the ligand-receptor complex. MDV 3100 has also been shown to induce tumor cell apoptosis, and has no agonist activity. MDV 3100 is a candidate for the treatment of castration-resistant prostate cancer. | | References | [1] Patent: WO2016/102482, 2016, A1. Location in patent: Page/Page column 114 [2] Patent: US9242996, 2016, B2. Location in patent: Page/Page column 248; 251 [3] Patent: WO2016/97004, 2016, A1. Location in patent: Page/Page column 108 |
| | tert-Butyl 2-bromo-4-fluorobenzoate Preparation Products And Raw materials |
|